title: Successful Desensitisation in a Patient with CRIM-Positive Infantile-Onset Pompe Disease.
abstract: Pompe disease (PD) is a severe life-threatening disease in which enzyme replacement therapy (ERT) with alglucosidase alfa is the only treatment available. Recently it has been shown that antibody formation may have a significant adverse effect on response to ERT. We report a cross-reactive immunologic material (CRIM)-positive PD infant who developed severe infusion-associated reactions (IARs) after 15 uneventful months of ERT. We successfully got the child to tolerate the ERT by a desensitisation protocol. We diluted the total amount of standard alglucosidase alfa infusion (20 mg/kg/dose) to 1/100 (0.2 mg/kg/dose). The original infusion rates were maintained. We doubled this dose every week. No premedication was given. In 8 weeks, we reached the standard dose without any IAR. No further reactions have been observed during 6 months of follow-up. Importantly, clinical deterioration that was observed during the period of reduced enzyme delivery has almost completely reversed. We conclude that this protocol was effective in our patient, while being safe and easy to follow, and may be suitable in selected cases.
authors.affiliation: Metabolic Medicine Department, Great Ormond Street Hospital, London, UK, jbaruteau@yahoo.fr.
authors.forename: J
authors.initials: J
authors.lastname: Baruteau
authors.forename: A
authors.initials: A
authors.lastname: Broomfield
authors.forename: V
authors.initials: V
authors.lastname: Crook
authors.forename: N
authors.initials: N
authors.lastname: Finnegan
authors.forename: K
authors.initials: K
authors.lastname: Harvey
authors.forename: D
authors.initials: D
authors.lastname: Burke
authors.forename: M
authors.initials: M
authors.lastname: Burch
authors.forename: G
authors.initials: G
authors.lastname: Shepherd
authors.forename: A
authors.initials: A
authors.lastname: Vellodi